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Abstract
The impact of tuberculosis and of anti-tuberculosis therapy on composition and modification
of human lung microbiota has been the object of several investigations. However, no clear
outcome has been presented so far and the relationship between M. tuberculosis pulmonary
infection and the resident lung microbiota remains vague. In this work we describe the
results obtained from a multicenter study of the microbiota of sputum samples from patients
with tuberculosis or unrelated lung diseases and healthy donors recruited in Switzerland,
Italy and Bangladesh, with the ultimate goal of discovering a microbiota-based biomarker
associated with tuberculosis. Bacterial 16S rDNA amplification, high-throughput sequencing
and extensive bioinformatic analyses revealed patient-specific flora and high variability in
taxon abundance. No common signature could be identified among the individuals enrolled
except for minor differences which were not consistent among the different geographical
settings. Moreover, anti-tuberculosis therapy did not cause any important variation in micro-
biota diversity, thus precluding its exploitation as a biomarker for the follow up of tuberculo-
sis patients undergoing treatment.
Introduction
Tuberculosis (TB) is a widespread infectious disease caused by Mycobacterium tuberculosis
which is transmitted through aerosol droplets containing bacilli released from infected indi-
viduals. In 2018, the World Health Organization estimated 10 million new TB cases worldwide
that led to 1.6 million fatalities, thus ranking TB as the main cause of death from a single path-
ogen [1].
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M. tuberculosis pathogenesis and outcome of TB infection are impacted by several factors
such as bacterial lineage [2], drug susceptibility of the strains [3], co-infection with HIV [4] or
Cytomegalovirus (CMV) [5], comorbidities like diabetes [6], genetic predisposing factors (for
instance IFN-γ/IL-12 deficiency [7]) and malnutrition [8].
One emerging host factor that may play a role in TB disease is the microbiota, which is
defined as the microbial community that inhabits several sites of the body, including gut [9],
vagina, lung and bladder [10–12]. Commensal microbial communities live in these mucosal
compartments and are believed to positively influence human health, by modulating the activ-
ity of the immune system, by enabling the elimination of ineffectively working immune cells
and by protecting the host from pathogens [11,13]. Disruption of the microbiota (dysbiosis)
caused by antibiotic treatment, nutritional factors or infections may lead to dysfunction of the
respective organs [14], thereby promoting disease. It has been shown that antibiotic therapy
can modify the composition of the microbiota and, in some cases, is associated with adverse
health effects in patients [15].
Anti-TB treatment is long (at least six months for drug-susceptible cases) and involves a
combination of narrow- as well as broad-spectrum drugs in regimens that may impact the
structure and composition of the microbial communities co-existing within the host. First-line
anti-TB treatment (composed of isoniazid, rifampicin, ethambutol and pyrazinamide) was
shown to have little effect on microbiota composition in the gut of TB patients, although the
relative abundance of some taxa (Lactobacillus and Prevotella) was found to be altered [16].
Studies conducted in the murine model of TB revealed that colonization of the gut by Heli-
cobacter hepaticus results in increased lung inflammation and pathology upon challenge with
M. tuberculosis [17,18]. On the other hand, it seems that H. pylori has the opposite effect [19].
Unfortunately, few investigations have been carried out so far in humans and these have had
contradictory results. One study reported no significant alteration in gut microbiota in indi-
viduals with latent TB infection [16] while another found changes in the abundance of short-
chain fatty acid-producing bacteria [20,21]. Interestingly, a study focused on one multidrug-
resistant TB case sampled during therapy discovered that the gut flora was depleted by long-
term treatment with second-line drugs [22]. Altogether, these data suggest the existence of an
interplay between commensal gut microbes and lung morbidities via the gut-lung axis. Specifi-
cally, metabolites produced by intestinal bacteria impact immune responses in the respiratory
tract as in the case of allergic asthma [23–25].
The interplay between microbiota of the respiratory tract and TB has been the object of var-
ious analyses, reviewed in [26–28]. Most of the human studies have been performed on spu-
tum samples or throat swabs and oropharyngeal secretions by means of 16S ribosomal DNA
(rDNA) amplification and sequencing. Overall, the findings are limited and inconsistent, with
high variability measured in different experimental settings. For example, Cui and colleagues
showed that active TB disease is associated with higher taxon diversity [29]. Another group
found few differences between TB cases and controls, limited to Mogibacterium, Moryella and
Oribacterium [30]. A third investigation reported that Streptococcus, Prevotella and Neisseria
spp. were more abundant in TB patients than in the healthy cohort [31]. On the contrary, Wu
and co-workers discovered that Prevotella was reduced in TB cases compared to healthy con-
trols [32], whereas Botero compared bacterial and fungal taxa found in sputum specimens to
those in nasal swabs in TB patients and reported that these were distinct [33]. On the other
hand, a study based on bronchoalveolar lavage discovered more Cupriavidus, Mycobacterium
and Porphyromonas in people with TB lesions and higher abundance of Streptococcus in con-
trols [34].
In this work we analyzed the taxonomic composition of sputum microbiota in TB patients
and in control subjects (either healthy donors or patients with lung disease different from TB)
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by means of 16S rDNA amplification from sputum samples. We report patient-specific micro-
bial communities, which precluded extrapolating common signatures. Additionally, antibiotic
TB treatment did not appear to drive any alterations in sputum microbiota composition or rel-
ative species abundance, thereby preventing the definition of a microbiota-based biomarker.
Results
Rationale and aim of the work
Previously, multiple studies have demonstrated how microbiota composition in gut, lungs and
skin impacts the clinical evolution of various pathologies, including inflammatory, auto-
immune and behavioral disorders as well as infectious diseases [35–40]. In this multicenter
study, we investigated the composition of sputum microbiota in TB disease and during anti-TB
treatment. More specifically, we recruited patients affected by pulmonary TB in different coun-
tries (mainly Bangladesh, Italy and Switzerland), thereby assessing the sputum microbiota of
different ethnic cohorts, and performed bacterial 16S rDNA amplification from their sputum
samples, followed by high-throughput sequencing. Our objectives comprised the following:
a. Analyze and compare the composition of sputum microbiota in TB patients and in control
subjects, not affected by TB disease but either healthy or affected by pneumonia.
b. Characterize the sputum microbiota in TB patients undergoing anti-TB therapy. In this
case, a time-course study was undertaken.
The overall goal of the study was the definition of a new biomarker, based on microbiota
composition.
Since patients were recruited in different countries at different times and may have been
subjected to different therapeutic protocols, we anticipated that a unique bioinformatic analy-
sis might be impossible to carry out and, most importantly, this would be scientifically weak.
While DNA preparation, 16S rDNA PCR amplification, library preparation and sequencing
followed the same protocols throughout the study, bioinformatic tools were optimized while
the study was ongoing. For these reasons, results will be presented separately.
First analyses of microbiota composition in sputum samples received from
FIND
To explore the diversity of sputum microbiota in TB patients and to compare it to that of
patients not affected by TB disease, we collaborated with FIND (Foundation for Innovative
New Diagnostics, Geneva, Switzerland), which provided access to the first samples analyzed.
The first batch of sputum samples included those obtained from 15 patients with active TB
and from 15 individuals without TB. None of these individuals were diagnosed as HIV posi-
tive. Non-TB samples were from patients coming from Canada (Winnipeg), The Gambia,
Spain (Barcelona), whereas Vietnam, Brazil (Salvador), The Gambia and Uganda represented
the countries where TB patients were sampled (Table 1).
The first parameter considered in the analysis was alpha diversity, which represents a mea-
sure of the taxonomic diversity of the samples and counts the number of distinguishable taxa
in each sample [41]. No significant difference was observed, indicating that TB and non-TB
specimens were equally diverse and there was no sample with a greater number of taxa identi-
fied (S1A Fig). When normalized Phylum abundances in the various samples were considered,
no hierarchical clustering was noted according to the disease (TB or non-TB) or to the region
of origin, therefore indicating high variability (Fig 1A). Similarly, Principal Component Analy-
sis (PCoA) did not display any segregation of the sputum samples (Fig 1B).
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The study was further extended to a geographically matched dataset that included 30 HIV
negative patients, 15 of which with active TB and 15 without. In each of the two groups, 8 sam-
ples came from Vietnam and 7 from South Africa (Table 2). As found in the previous
unmatched analysis, alpha diversity was similar for the two groups at all taxonomic levels (S1B
Fig). Analysis of taxonomic composition by hierarchical clustering revealed clear segregation
of TB and non-TB samples at the Family level whereas no impact of the country of origin was
noticed (Fig 2A and 2B and S2A Fig). Interestingly, the sequencing batch had a minor effect, if
any, on the results obtained (Fig 2A and S2A Fig). PCoA partially segregated bacterial Families
belonging to Bacteroidetes from those belonging to Fusobacteria on PC1 and Proteobacteria
Families from Firmicutes Families on PC2 (S2B Fig), suggesting differences in the abundance
profiles for these taxa. Furthermore, differential abundance analysis revealed Lachnospiraceae
(Phylum Firmicutes) as one of the Families characterized by absolute log2 fold-change greater
than 1 and adjusted p-value lower than 0.05 (Fig 2C).
Microbial diversity in patients recruited in Switzerland
To extend the study to a different geographical setting and to characterize the evolution of spu-
tum microbiota during anti-TB therapy, 10 TB patients from Switzerland were evaluated
(Table 3). Induced sputum samples were collected at different time-points throughout therapy,
i.e. 0, 2, 4, 8 weeks, 5 and 6 months. Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria
and Proteobacteria represented the major Phyla identified in these samples (Fig 3A and 3B).
When normalized Phylum abundances were calculated, a statistically significant change was
observed for Bacteroidetes between time-point 0, which showed the highest level, and the
other time-points (Fig 3A). On the other hand, the heatmap in Fig 3B illustrates the variability
observed in Phylum abundances among the different patients and time-points. Detailed analy-
sis of the mean and median values of the aggregated samples confirmed that Bacteroidetes,
and the corresponding downstream taxonomic levels (i.e. Class Bacteroidia, Order Bacteroi-
dales, Family Prevotellaceae, Genus Prevotella and Species Prevotella melaninogenica), were
the predominant taxa at time-point 0 and their abundance gradually decreased with time (S3
Fig).
Table 1. Characteristics of the first batch of samples received from FIND.
Pulmonary TB Non-TB samples Total
Sputum samples (%) 15 (50) 15 (50) 30 (100)
Median age in years (range) 37 (22–74) 48 (18–78) 43 (18–78)
Female gender (%) 5 (33) 5 (33) 10 (33)
Origin (%) Vietnam 8 (53) 0 8 (27)
Brazil(Salvador) 2 (13) 0 2 (7)
Uganda 4 (27) 0 4 (13)
The Gambia 1 (7) 5 (33) 6 (20)
Canada(Winnipeg) 0 5 (33) 5 (17)
Spain (Barcelona) 0 5 (33) 5 (17)
BCG N (%) Vaccinated 8 (53) 3 (20) 11 (37)
Unvaccinated 1 (7) 7 (47) 8 (27)
Unknown status 6 (40) 5 (33) 11 (37)
Smokers (%) 4 (27) 5 (33) 9 (60)
Chronic alcoholism (%) 5 (33) 1 (7) 6 (20)
TB: Tuberculosis; BCG: Bacillus Calmette–Guérin vaccine. Information about BCG vaccination, smoking and alcoholism was collected from clinical records.
https://doi.org/10.1371/journal.pone.0240250.t001
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Microbial diversity in patients recruited in Italy
Recruitment of an additional set of samples at the National Institute for Infectious Diseases in
Rome (Italy) allowed comparisons between patients affected by TB or by pneumonia (details
are shown in Table 4). Overall, twenty-two patients were part of the study: 10 of these were
diagnosed with active TB, whereas among the 12 patients without TB, 11 had pneumonia and
1 had a lung abscess. Sputa were collected from all of them at different time-points during
therapy. Specifically, most of the TB patients were sampled at 0, 2 weeks, 4 weeks, 8 weeks, 5
months and 6 months after therapy started. However, depending on the severity of the disease
Fig 1. Analysis of the first batch of samples received from FIND. A. Heatmap of Phylum abundances across samples. Hierarchical clustering did not segregate the data
according to disease (TB in violet, non-TB in green) nor to the region of origin. B. PCoA (PC1 vs. PC2) displaying all of the samples, colored according to the country. The
different shapes (triangle or circle) indicate TB and non-TB samples, respectively. No segregation could be observed. The percentage of variance explained for the first
components is shown in the inset.
https://doi.org/10.1371/journal.pone.0240250.g001
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and on patient compliance with the experimental clinical protocol, sputum from some of them
was collected at months 9, 10 and 11. For the same reasons, collection of the expectorate from
members of the control group was performed at months 0, 2, 3, 4, 5, 6 and 7 after therapy
began. To avoid sequencing batch effects, the sequencing libraries of all samples were pooled
and sequenced together.
Analysis of 16S rDNA Illumina reads proved that sequencing coverage was excellent for all
of the samples, with more than 99.7% of the reads mapping to the Greengenes database [42].
S4 Fig shows the most abundant Phyla identified in the samples (Firmicutes, Bacteroidetes,
Actinobacteria, Proteobacteria, Fusobacteria, TM7, Tenericutes, SR1 and Spirochaetes) and
Table 2. Characteristics of the second batch of samples received from FIND.
Pulmonary TB Non-TB samples Total
Sputum samples (%) 15 (50) 15 (50) 30 (100)
Median age in years (range) 40 (22–61) 44 (29–72) 41 (22–72)
Female gender (%) 3 (20) 3 (20) 6 (20)
Origin (%) Vietnam 8 (53) 8 (53) 16 (53)
South Africa 7 (47) 7 (47) 14 (47)
BCG N (%) Vaccinated 7 (47) 8 (53) 15 (50)
Unvaccinated 5 (33) 4 (27) 9 (30)
Unknown status 3 (20) 3 (20) 6 (20)
Smokers (%) 8 (53) 8 (53) 16 (53)
Chronic alcoholism (%) 4 (27) 4 (27) 8 (27)
TB: Tuberculosis; BCG: Bacillus Calmette–Guérin vaccine. Information about BCG vaccination, smoking and alcoholism was collected from clinical records.
https://doi.org/10.1371/journal.pone.0240250.t002
Fig 2. Analysis of the second batch of samples received from FIND. A. Heatmap of Family abundances across samples. The hierarchical clustering shows a
segregation for the majority of the TB (violet) and non-TB samples (green). No segregation is observed for the sequencing batch or the region of origin. Annotations of
rows provide the strengths and significances of Families in TB samples compared to non-TB samples (differential abundance analysis–see methods - significant if
absolute log2 Fold-Change> 1 and adjusted p-value< 0.05). B. Barplots quantifying the representations of TB and non-TB samples in the two clusters obtained in A as
well as their region of origin. C. Abundance distributions of representative Families identified in A in TB and non-TB samples.
https://doi.org/10.1371/journal.pone.0240250.g002
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highlights the high variability observed. After normalization to sequencing depth and identifi-
cation of the bacterial taxa represented in each sample, alpha diversity was calculated using the
Faith Phylogenetic Diversity and the Shannon index. Overall, no correlation between time
Table 3. Demographic characteristics of the subjects enrolled at the Centre Hospitalier Universitaire Vaudois
(CHUV) in Lausanne, Switzerland.
Pulmonary TB patients�
Enrolled subjects (%) 10 (100)
Median age in years (range) 38 (23–68)
Female gender (%) 6 (60)
Origin (%) Western Europe (Switzerland, %) 3 (30)
Eastern Europe (Romania, %) 2 (20)
Africa (%) 4 (40)
West Asia (%) 1 (10)
Smokers (%) 7 (70)
TB:Tuberculosis
�One patient was diagnosed with multi-drug resistant TB. Information about smoking was collected from clinical
records.
https://doi.org/10.1371/journal.pone.0240250.t003
Fig 3. Analysis of samples received from CHUV. A. Phylum abundances per time-points. A significant change could only be observed for Bacteroidetes between time-
point 0 and the other five time-points (pairwise t-test, with adjusted p-value< 0.01). B. Heatmap of Phylum abundances across samples and scaled by bacteria.
Hierarchical clustering was applied to Phyla. Samples are ordered by patient (different colors) and by time-point (TP).
https://doi.org/10.1371/journal.pone.0240250.g003
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points was observed (Shannon: Pearson 0.1963, p-value 0.0566; Spearman 0.1807, p-value
0.0796; Faith: Pearson 0.2656, p-value 0.0093; Spearman 0.2228, p-value 0.0300), and the Krus-
kal-Wallis test revealed no significant difference between TB patients and patients with an
unrelated lung disease (S5 Fig), and modest differences between the time-points (S6 Fig). Beta
diversity calculation (i.e. quantitative measure of community dissimilarity) was calculated
using the Bray-Curtis dissimilarity test [43] (based on abundances), the Jaccard index (based
on the presence or absence of species) and unweighted and weighted UniFrac [44] methods
(the latter incorporates phylogenetic relationships). PCoA did not reveal any clustering of
either disease status or time-point for any of the methods mentioned above (Fig 4 shows
Table 4. Demographic characteristics of the subjects enrolled at the National Institute for Infectious Diseases in Rome, Italy.
Pulmonary TB� Pneumonia�� Total
Enrolled subjects (%) 10 (45) 12 (55) 22 (100)
Median age in years (range) 36 (25–60) 51 (28–74) 40 (25–74)
Female gender (%) 2 (20) 4 (33) 6 (27)
Origin (%) Italy (%) 3 (30) 11 (92) 14 (64)
Romania (%) 7 (70) 1 (8) 8 (36)
BCG N (%) Vaccinated (%) 7 (70) 1 (8) 8 (36)
Unvaccinated (%) 3 (30) 11 (92) 14 (64)
Antibiotic therapy before starting in-hospital therapy (%)��� 6 (60) 10 (83) 16 (73)
Smokers (%) 9 (90) 3 (25) 12 (54)
Mild Grade (%) 0 4 (33) 4 (18)
Chest X-ray (%) Intermediate Grade (%) 1 (10) 6 (50) 7 (32)
High Grade (%) 9 (90) 2 (17) 11 (50)
Diabetes 0 0 0
TB: Tuberculosis
�all TB cases were microbiologically confirmed; BCG: Bacillus Calmette–Guérin vaccine
��among the pneumonia patients, a subject affected by lung abscess was included
��� The therapy consisted of cephalosporins or macrolides. Sputum was collected within 7 days after therapy started (after 2 days on average). Information about BCG
vaccination, smoking and diabetes was collected from clinical records.
https://doi.org/10.1371/journal.pone.0240250.t004
Fig 4. Principal component analysis (PCoA) of the sputum samples collected in Italy, based on Bray-Curtis
distances. A. Samples collected from tuberculosis (TB) patients. The different colors indicate the various time-points.
B. Samples collected from pneumonia (nonTB) patients. The different colors correspond to the various time-points.
https://doi.org/10.1371/journal.pone.0240250.g004
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the Bray-Curtis PCoA, PERMANOVA pseudo-F = 1.096, p-value = 0.137). No significant
diversity between TB and non-TB patients was found for any of the beta diversity measures
(PERMANOVA method, with 999 permutations: Jaccard, pseudo-F = 1.087, p-value = 0.051;
Unweighted Unifrac, pseudo-F = 1.923, p-value = 0.001; Weighted Unifrac, pseudo-F = 1.711,
p-value = 0.135).
Differential abundance analysis was obtained by using ANCOM (Analysis of composition
of Microbiomes [45]) and the Gneiss method [46]. Statistical analysis for the ANCOM study
was not significant. Upon analysis of the differential abundance of the various taxa, the Gneiss
method proved that more than 70% of the community variation was due to variability among
subjects and less than 20% could be attributable to other factors, such as sample groups or
time-points (S7 Fig).
Finally, volatility analysis assessed how volatile a dependent variable was over a continuous,
independent variable (i.e. time) in one or several groups. The Shannon alpha diversity index
did not show any consistent time-dependent change in TB patients compared to non-TB
patients, as illustrated in S8 Fig.
In summary, there were no differentially abundant features over time in the group of TB or
control patients recruited in Italy.
Microbial diversity in patients recruited in Bangladesh
The last group of sputum samples was collected at the “icddr,b institute” in Bangladesh, where
11 TB patients were recruited. These were sampled at different time-points throughout ther-
apy, together with 10 healthy donors, who were sampled only once. Demographic and clinical
features of the subjects enrolled are detailed in Table 5.
Technical issues (some sputa could not be collected, failure of library preparation or unsuc-
cessful sequencing for other samples) excluded 2 healthy donors and 5 TB time-points from
downstream analyses. Sequencing coverage was good in all of the remaining samples, with
>99.5% of the reads mapping to the Greengenes [42] dataset.
S9 Fig lists the most abundant Phyla identified in the samples, which overall matched those
previously noticed in the sputa collected in Italy, that is: Firmicutes, Bacteroidetes, Actinobac-
teria, Proteobacteria, Fusobacteria, TM7, Tenericutes, SR1 and Spirochaetes. As reported for
the Italian patients, high variability was observed among the Bangladeshi individuals as well.
Alpha diversity was calculated for these samples as described above for the Italian cohort. No
significant variation in alpha diversity was observed between the healthy donors and the TB
Table 5. Demographic characteristics of the subjects enrolled at the icddr,b, Dhaka, Bangladesh.
Smear positive pulmonary TB patients Healthy controls� Total
Enrolled subjects (%) 11 (52) 10 (48) 21 (100)
Median age in years (range) 35 (24–50) 24 (23–25) 29 (23–50)
Female gender (%) 3 (27) 0 (0) 3 (14)
Diabetes (%) Status known (%) 7 (64) 8 (80) 15 (71)
Yes (%) 3 (43) 0 3 (20)
Smokers (%) 7 (64) 9 (90) 16 (76)
Alcohol abusers (%) 0 4 (40) 4 (19)
Drug abusers (%) 0 0 0
TB: Tuberculosis
�Healthy controls had no symptoms suggestive of TB during the period of enrolment. Only two controls were exposed to TB patients in their family. Information about
smoking, alcoholism and drug abuse was collected from clinical records.
https://doi.org/10.1371/journal.pone.0240250.t005
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Fig 5. Alpha diversity for the sputum samples received from Bangladesh. A. Faith Phylogenetic Diversity. B. Shannon index. Samples from controls and TB
patients are listed on the X-axis. TB patients are grouped according to the time-point. Grey dots represent outliers. Pairwise Kruskal-Wallis statistics are shown
for p-values smaller than 0.05. The “patient ALL” group (red) was tested separately against the controls (test not statistically significant). Kruskal-Wallis test for
all groups was 19.05 (p-value 0.004) for Faith Phylogenetic Diversity and 14.94 (p-value 0.021) for Shannon index.
https://doi.org/10.1371/journal.pone.0240250.g005
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group (Kruskal-Wallis: Faith Phylogenetic Diversity, H = 1.45, p-value = 0.2; Shannon index,
H = 2,94, p-value = 0.09). In contrast to the Italian cohort, a modest decrease in alpha diversity
was evident in TB patients after 2 weeks of anti-TB therapy as compared to healthy donor sam-
ples (Faith Phylogenetic Diversity, Kruskal-Wallis p-value = 0.026) and compared to TB sam-
ples at time-point 0 (Faith Phylogenetic Diversity, Kruskal-Wallis p-value = 0.005) (Fig 5). In
addition, a PCoA analysis according to Bray-Curtis was performed as well to check whether
samples clustered according to any metadata (i.e. control or TB, different time-points). Fig 6
shows that no clear grouping was possible. No significant difference between groups was
found using the Jaccard index (PERMANOVA pseudo-F 1.317, p-value 0.056) and the
unweighted and weighted UniFrac (PERMANOVA pseudo-F 1.115, p-value 0.32, and pseudo-
F 3.272, p-value 0.035, respectively) (S10 Fig).
Differential abundance analysis was calculated by ANCOM [45] and Gneiss methods [46],
as described for the samples collected in Italy. Significance for the ANCOM study was weak
and not significant. Furthermore, Gneiss analysis of the differential abundance of the various
taxa showed that most of the variability was due to variation between subjects and only about
5% was attributable to time (S11 Fig). Similarly to the observations made with samples
obtained in Italy, no microbial pattern, i.e. no differentially abundant features, could be identi-
fied in either of the groups. Indeed, each patient was characterized by a specific microbiota
profile, which did not allow extrapolation to a common signature.
Finally, volatility analysis evaluated variability of the alpha diversity over time. The Shannon
index did not change during the 6-month timeframe in TB patients (S12 Fig). Therefore,
results obtained with the cohort from Bangladesh confirmed the absence of features that are
significantly and differentially abundant in people with active TB compared to those without
the disease, at the time of diagnosis as well as over time.
Discussion
Robust biomarkers that allow diagnosis of active, latent or re-activated TB disease and follow-
up of TB patients during chemotherapy play a pivotal role in defining clinical interventions
Fig 6. Principal component analysis (PCoA) of the sputum samples collected in Bangladesh. The analysis is based
on Bray-Curtis distances and shows control and TB patients at the different time-points.
https://doi.org/10.1371/journal.pone.0240250.g006
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[47,48]. In addition to medical examination, a few biomarkers are nowadays available and
comprise sputum conversion analysis, macrophage activation markers and detection of myco-
bacterial DNA, lipoarabinomannan or chemokines in urine samples [49–53]. Unfortunately,
some of these biomarkers are of limited use in paucibacillary and pediatric TB, and of little or
no use in latent TB, whereas others suffer from lack of consistency or limited applicability in
specific settings. IFN-γ-release assays (IGRAs) such as QuantiFERON-TB Gold Plus and
T-SPOT TB tests, measure responses to antigens (e.g. ESAT-6 or CFP-10) that discriminate
infection from immunity induced by vaccination but not between active disease and latent M.
tuberculosis infection [54].
The hypothesis that underpinned this study was that exploration of the sputum microbiota
could identify and define a new class of microbiota-based biomarkers that might complement
existing tools. To address this question, multicenter studies were undertaken to characterize
sputum microbiota in the context of TB disease. Of these, three were independent prospective
cohort studies. Results, based on 16S sequence analysis, revealed minor and inconsistent dif-
ferences in microbial abundance in sputum samples.
No difference in alpha diversity was observed in TB or pneumonia patients. Only the Ban-
gladeshi cohort showed a reduction of the alpha diversity 2 weeks after anti-TB therapy was
initiated, and this then gradually increased with time. Interestingly, the microbial profiles of
the people recruited in Dhaka seemed to be more homogeneous than those of the Italian
cohort possibly because the latter showed more ethnic diversity.
Only sporadic, if any, differences were detected. Taxonomic composition varied greatly
among patients and time points. This was especially obvious for the most prevalent species like
Streptococcus and Prevotella, which in some samples accounted for the majority of the micro-
biome. Our analyses did not identify any particular taxon that was correlated with TB disease.
Previous studies of sputum microbiota were mainly conducted in China [29,30,32,34],
Colombia [33] and India [31] thus making correlations with our study difficult. Moreover,
most of the reports mentioned above were based on a single sample, collected before antibiotic
treatment. Therefore, it is difficult to extrapolate any similarity or difference with the Italian
and Bangladeshi group, which are characterized by a time-course analysis. On the other hand,
a tentative comparison can be made with our FIND and CHUV cohorts. For instance,
increased abundance of Neisseriaceae was noted in TB patients from the second FIND group,
similarly to what was reported by Krishna and colleagues [31]. Bacteria belonging to the Bac-
teroidetes Phylum were found to be the most abundant in the CHUV set at time-point 0 and
were also identified by Wu and colleagues [32] as among the most affected in their relative
abundance studies.
The present work relies on collection of spontaneous or induced sputum samples, which
may be contaminated by the microbial flora of the upper respiratory tract and therefore may
not truly represent the microbial population in the lungs. Accurate lung sampling would
require bronchoalveolar lavage but use of this rather invasive technique is unethical in a longi-
tudinal study such as the one presented here.
This study is based on five datasets, each of which includes between 11 and 30 samples, split
among TB and non-TB individuals. While these numbers fall within the order of magnitude of
the sample size of previous works [30,31,33], the definition of a generic biomarker might
require even bigger sample sets.
A possible limitation of this investigation was that M. tuberculosis was of seemingly low
abundance as evidenced by 16S rDNA sequencing although the primers used for PCR success-
fully amplified the correct DNA fragment from purified genomic DNA. The reason for this is
unknown although a study by Sulaiman and colleagues reported the same observation, i.e. the
limitation of 16S rDNA amplification and sequencing in detecting mycobacteria in airway
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samples [55]. A more powerful approach for analysing the composition of sputum and lung
microbiota could be metagenomics, possibly combined with transcriptomic and metabolomic
analyses. While these procedures have been applied successfully to investigate the gut micro-
biota [56], the small amount of material that can be extracted from lung or sputum samples
may limit their exploitation.
In conclusion, no association between the sputum microbiota composition and TB disease,
or variation throughout anti-TB treatment, could be found in three different settings.
Materials and methods
Sample collection at the Foundation for Innovative New Diagnostics
(FIND), Geneva, Switzerland
A request for sputum samples from HIV-negative TB and non-TB patients was submitted to
The Foundation for Innovative New Diagnostics (FIND) by the laboratory of Prof. Cole at
EPFL in November 2013 and then again in June 2014. The requests were reviewed by the
FIND Specimen Bank Review Committee and approved. FIND donated thirty sputum samples
originated from TB (15) and non-TB (15) individuals in November 2013. A second batch of
samples, including 15 TB and 15 non-TB, was donated by FIND in June 2014. Non-TB indi-
viduals had been subjected to microbiological testing to rule out TB. Induced sputum samples
were shipped frozen to EPFL for DNA preparation, 16S rDNA amplification, sequencing and
bioinformatic analysis. Tables 1 and 2 show socio-demographic data of the patients whose
samples were received from FIND.
Study approval and sample collection at Centre Hospitalier Universitaire
Vaudois (CHUV) in Lausanne, Switzerland
The study was approved by the Commission Cantonale d’étique de la Recherche sur l’être
humain (CER-VD) with protocol 35/09. Written informed consent was obtained from ten
HIV-negative patients diagnosed with culture-positive, pulmonary TB, who were enrolled in
the study. Induced sputum samples were collected, decontaminated in (NALC/NaOH), stored
at -80˚C and shipped to EPFL for DNA preparation, 16S rDNA amplification, sequencing and
bioinformatic analysis. Table 3 shows socio-demographic data of the subjects enrolled in
Switzerland.
Study approval and sample collection at the National Institute for
Infectious Diseases (INMI) “L. Spallanzani” in Rome, Italy
The study was approved by the Ethics Committee of the National Institute for Infectious Dis-
eases “L. Spallanzani” IRCCS with the “PARERE n. 98/2014” (October 20th, 2014) and all
enrolled patients provided written informed consent. Twenty-two HIV-negative patients hos-
pitalized for suspected pulmonary TB from November 2014 to July 2015 at “L. Spallanzani”
Hospital for Infectious Diseases in Rome were enrolled. Among the 22 patients, 10 had cul-
ture-confirmed TB and 12 had pneumonia.
Patients with active TB. TB symptom screening was conducted according to internal
guidelines of the National Institute for Infectious Diseases “L. Spallanzani” (Protocollo INMI
di Gestione Clinica della Tubercolosi- Revisione N.7-Gennaio 2020 www.inmi.it/protocolli_e_
linee_guida.html).
Culture-confirmed TB was defined as at least one positive culture for M. tuberculosis sensi-
tive to first-line drugs from spontaneous or induced sputum. In particular, 8 patients were
Acid Fast Bacilli (AFB) sputum smear positive and 2 AFB sputum smear negative; however,
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these 2 sputa were positive upon nucleic acid amplification (Xpert MTB/RIF assay; Cepheid,
United States). Culture was performed on both solid media (proportion method in Lowen-
stein-Jensen medium) and liquid media (MGIT 960 systems; Becton Dickinson, Sparks, MD,
USA).
Six TB patients out of 10 had been taking cephalosporins for maximum 2 days before being
sampled. For treatment-naïve patients (4 out of 10), the first sputum sample was collected
within 72 hours of the beginning of TB therapy. Initial treatment was provided on an in-hospi-
tal basis, until AFB sputum conversion (Xpert MTB/RIF assay) was achieved on three consecu-
tive negative samples collected during one week. After discharge, patients were followed
monthly on ambulatory care for the full course of treatment (6 months). Treatment outcome
was successful (culture negative and asymptomatic patient) in all 10 TB patients.
Patients with pneumonia (non-TB). Community-acquired pneumonia was defined as an
acute infection of the pulmonary parenchyma that was associated with at least some symptoms
of acute infection, accompanied by the presence of an acute infiltrate on a chest radiograph, in
patients not hospitalized or residing in a long-term care facility for more than 14 days before
onset of symptoms. All pneumonia patients were AFB sputum smear negative and culture neg-
ative for M. tuberculosis. A patient with lung abscess was also included in the group.
For both TB and pneumonia samples, from the second month of treatment onwards, all
sputa were induced. All samples were decontaminated in N-acetyl-L-cysteine-sodium hydrox-
ide (NALC/NaOH), stored at -80˚C and shipped to EPFL for DNA preparation, 16S rDNA
amplification, sequencing and bioinformatic analysis. Table 4 shows socio-demographic data
of the Italian cohort.
Study approval and sample collection at the icddr,b, Dhaka, Bangladesh
This study was approved by the Research Review Committee (RRC, 21 April 2014) and Ethical
Review Committee (06 August 2014) of icddr,b. Patient enrolment started from 26 April 2014
just after receiving clearance from RRC. Newly registered smear positive pulmonary TB (PTB)
patients were selected from Shyamoli Hospital, Dhaka on the basis of convenience to ensure
follow up. Healthy volunteers (controls) were enrolled from the attendants of the patients visit-
ing icddr,b Dhaka Hospital. All enrolled individuals gave written informed consent to partici-
pate in the study. The controls were free from any clinical symptom suggestive of TB at the
time of enrolment and had no previous history of TB. TB symptom screening was conducted
according to internal guidelines of the icddr,b, Dhaka. Sputum microbiological testing was
performed to rule out TB in healthy controls.
Specimen collection. Upon informed consent, HIV-negative TB patients and controls
were brought into an isolated room of both respective study sites for sample collection.
Induced sputum specimens were collected from all the controls and from the PTB patients
who were unable to cough a good quality sputum specimen especially during the later stages of
treatment. Sputum specimens were collected with all aseptic precautions and by expert physi-
cians/nurses only. The specimens were collected from the PTB patients at six time-points over
the course of the 6-month anti-TB treatment: Day 0 (when the diagnosis is made, during
enrolment), 2 weeks post-treatment initiation (1st follow up), 4 weeks post-treatment initiation
(2nd follow up), 8 weeks post-treatment initiation (3rd follow up), 5 months post-treatment ini-
tiation (4th follow up) and 6 months post-treatment initiation (5th follow up).
Regarding controls, induced sputum specimens were collected only during enrolment.
In the Bangladeshi cohort, four out of the 15 enrolled smear-positive PTB patients dropped
out just after enrolment. Therefore, they were excluded from specimen analysis. Of the
remaining 11 patients, two were lost to follow up at their last time point (end of treatment).
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We could complete all the follow-ups for the remaining 9 TB patients. On the other hand, 10
healthy controls were enrolled and single induced sputum from each of them was collected.
After collection, specimens were transported to the icddr,b Mycobacteriology Laboratory
on the same working day. All the specimens were processed and decontaminated there accord-
ing to standard NALC/NaOH method. The processed specimens were stored and shipped at
-20˚C to Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland for DNA prepara-
tion, 16S rDNA amplification, sequencing and bioinformatic analysis. A total of 74 sputum/
induced sputum specimens from all study participants were collected. Table 5 shows socio-
demographic data of 11 PTB patients and 10 controls.
DNA extraction from sputum samples
Sputum samples were stored at -80˚C until use. DNA was extracted from the sputum samples
obtained in Italy and in Bangladesh with the QIAmp UCP Pathogen Mini kit (Qiagen),
according to the manufacturer’s recommendations. Sputum samples obtained in Switzerland
(CHUV and FIND) were processed with the MagNa Pure 96 System and MagNa Pure LC
DNA Isolation kit (Roche), according to the protocols provided by the manufacturer. Purified
DNA was quantified by Qubit fluorometer (Life Technologies). These manipulations were per-
formed under Biosafety Level 3 (BSL3) containment.
16S rDNA amplification, library preparation and high-throughput
sequencing
PCR amplification of two variable (V1-V2) regions (349 bp) of the 16S RNA gene was carried
out using primers 5’-AGR GTT YGA TYM TGG CTC AG-3’ and 5’-TGC TGC CTC CCG
TAG GAG T-3’ (Microsynth AG, Switzerland), where “R” could be A or G, “Y” could be C or
T, “M” could be A or C [30]. Platinum PCR Super Mix High Fidelity (Life Technologies) was
used, according to the manufacturer’s recommendations, with a no template sample as a nega-
tive control. PCR products were purified by MinElute PCR Purification Kit (Qiagen) and
quantified using Qubit (Life Technologies). Sequencing libraries were prepared with the Tru-
Seq ChIP Sample Prep Kit (Illumina) starting from 10 ng of PCR-amplified DNA and checked
by Qubit and Fragment Analyzer (Agilent) before loading the sequencing cell. Multiplexed (S1
Table) high-throughput sequencing was performed at the Ecole Polytechnique Fédérale de
Lausanne on a MiSeq instrument (Illumina), with MiSeq Reagent kit V2 500 cycles (Illumina),
where libraries were diluted to 8 pM and pooled according to the origin of the sputum sam-
ples. PhiX (PhiX Control V3, Illumina) was spiked in (15%) to generate diversity in the
sequencing clusters.
Bioinformatic analysis
Please refer to S1 Table for sequencing statistics. The sets of samples from FIND and the spu-
tum samples received from CHUV were analysed as follows. Sequences were quality trimmed
with Trimmomatic [57] and paired reads were merged with SeqPrep [58]. Sequencing reads
were mapped against Greengenes [42] v13.5 using bowtie2 [59], with the following parameters:
-k 50 (50 alignment matches), -N 1 (only 1 mismatch), -L 20 (seed length of 20 nt),—end-to-
end -p 5. For each Greengene ID, the counts were obtained by summing up the number of
reads mapped to the genes, corrected for multiple hits (reads with multiple hits mh were
counted as 1/mh). Bacteria represented in less than 10 samples were filtered out. Raw counts
were then normalized prior to further analysis to modified z-scores, that is log counts were
normalized to the sample medians and to the Median Absolute Deviation (MAD). Statistical
analysis was obtained in R (version 3.3.1, https://www.r-project.org/) using standard packages
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(e.g. stats, base, utils) as well as limma (v. 3.28, https://www.bioconductor.org/packages/
release/bioc/html/limma.html) for differential abundance analysis, and ggplot (v. 2.3, https://
ggplot2.tidyverse.org/reference/). PCoA plots were obtained by applying the prcomp method
(R package stats) on centered and scaled normalized abundances. Clusters were obtained from
normalized and scaled abundances, running a hierarchical clustering (using the hclust method
from the R package stats) based on a Pearson correlation distance. Heatmaps were plotted
using the R package pheatmap (v.1.0). Differential abundance analyses were performed using
the R package limma (v. 3.28). Significant bacteria were selected using an absolute log2 Fold-
change of 1 and an adjusted p-value (FDR) of 0.05.
The samples from Italy and Bangladesh were analysed in the QIIME2 package (v. 2018.8)
[60], using Greengenes v13.8 as the reference database. Greengenes 97% similarity set was
used. OTUs were picked using the default parameters and the “—enable_rev_strand_match”
option. Data was rarefied for even depth after reviewing the OUT table. The quality filter was
set to 30 (quality-filter module) and deblur was used for denoising the reads. Sklearn (https://
scikit-learn.org/stable/) was used for the taxonomy classification. The Naive Bayes classifier
was trained on the targeted 16S region of the 99_otus Greengenes dataset (extracted using the
primer sequences (see above) and the feature-classifier extract-reads module).
Supporting information
S1 Fig. Alpha diversity of the first (A) and second (B) batch of sputum samples received from
FIND. The Shannon index was calculated at the Phylum, Class, Order, Family and Genus lev-
els. TB samples are in violet, non-TB samples are in green. p-values of individual two-sided t-
tests are shown.
(PDF)
S2 Fig. Analysis of the second batch of samples received from FIND. A. PCoA (PC1 vs.
PC2) displaying the samples, colored by sequencing batch, shaped by TB and filled by country.
The total variance explained for the first components is shown in the inset. PCoA scores are
shown in the boxplots below the graph. Segregation of TB and non-TB samples was noted on
PC1. B. PCoA (PC1 vs. PC2) on bacteria, colored by Phylum. Bacteroidetes and Fusobacteria
tend to segregate on PC1, while Firmicutes and Proteobacteria segregate on PC2. The boxplots
show PC1 and PC2 scores per Phylum.
(PDF)
S3 Fig. Heatmaps of mean (top) and median (bottom) abundances for samples received from
CHUV. Hierarchical clustering was applied to all taxonomical levels (Phylum, Class, Order,
Family, Genus and Species). Samples are ordered by time-point.
(PDF)
S4 Fig. Taxonomy of the sputum samples received from Italy at the Phylum level. Samples
from TB and non-TB patients are listed on the X-axis and grouped according to the time-
point. The relative abundance of each Phylum is indicated on the Y-axis.
(PDF)
S5 Fig. Alpha diversity (Faith Phylogenetic Diversity in A and Shannon index in B) for the
sputum samples received from Italy. Samples from TB and non-TB patients were grouped and
are indicated on the X-axis. Results of Kruskal-Wallis test are reported in the figure. p-value
thresholding: 0.01.
(PDF)
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S6 Fig. Alpha diversity for the sputum samples received from Italy. A. Faith Phylogenetic
Diversity. B. Shannon index. Samples from TB and non-TB patients, grouped according to the
time-point, are listed on the X-axis. Grey dots represent outliers. Pairwise Kruskal-Wallis sta-
tistics are shown for p-values smaller than 0.05. Kruskal-Wallis test for all groups was 13.9 (p-
value 0.126) for the Faith Phylogenetic Diversity and 13.89 (p-value 0.123) for the Shannon’s
index.
(PDF)
S7 Fig. Gneiss analysis to infer features that are differentially abundant in sputum samples
received from Italy. The figure shows a dendrogram heatmap of relative abundances between
sets of taxa (balances). Individual samples likely contributed to the most prominent balances.
(PDF)
S8 Fig. Volatility analysis for the sputum samples received from Italy measured by the
Shannon index. Continuous black bar: global mean. Error bars are shown. Global control lim-
its (+/- 2x and 3x standard deviations from global mean) are indicated by dotted bars.
(PDF)
S9 Fig. Taxonomy at the Phylum level of the sputum samples received from Bangladesh.
Samples from controls or TB patients are listed on the X-axis and grouped according to the
time-point. The relative abundance of each Phylum is indicated on the Y-axis.
(PDF)
S10 Fig. Principal component analysis (PCoA) of the sputum samples collected in Bangladesh,
based on the Jaccard (A) and Unifrac (B) distances. No segregation was noted.
(PDF)
S11 Fig. Gneiss analysis to infer features that are differentially abundant in sputum sam-
ples received from Bangladesh. The figure shows a dendrogram heatmap of relative abun-
dances between sets of taxa (balances). Individual samples likely contributed to the most
prominent balances.
(PDF)
S12 Fig. Volatility analysis for the sputum samples received from Bangladesh measured by
the Shannon index. Continuous black bar: global mean. Error bars are shown. Global control
limits (+/- 2x and 3x standard deviations from global mean) are indicated by dotted bars.
(PDF)
S1 Table. Sequencing statistics.
(XLSX)
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